z-logo
Premium
Dissociation of co‐regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians
Author(s) -
Woolhouse N M,
Eichelbaum M,
Oates N S,
Idle J R,
Smith R L
Publication year - 1985
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1985.81
Subject(s) - sparteine , debrisoquine , phenformin , chemistry , population , urine , excretion , metabolism , endocrinology , medicine , pharmacology , biology , cyp2d6 , biochemistry , stereochemistry , diabetes mellitus , metformin , environmental health , cytochrome p450
The ability to oxidize sparteine to form 2‐ and 5‐dehydrosparteine was studied in 154 healthy Ghanaians. Although the urinary metabolic sparteine/dehydrosparteines ratio varied widely (from 0.14 to 12.5), in contrast to observations in several Caucasian population groups the ratios were not bimodally distributed and no phenotypically poor oxidizers of sparteine were found. The ability of these same subjects to oxidize debrisoquin and phenformin was also studied in 141 and 143 subjects. Of the 141 subjects dosed with debrisoquin, 10 proved to be poor oxidizers, and of the 143 subjects dosed with phenformin, 11 were poor oxidizers. All the poor oxidizers of debrisoquin were also poor oxidizers of phenformin. The 10 confirmed poor metabolizers of debrisoquin, who had debrisoquin metabolic ratios ranging from 14.4 to 52.0, had sparteine metabolic ratios ranging only from 0.15 to 12.5. Whereas Caucasian poor metabolizers of sparteine excrete <2.0% of a dose as dehydrosparteines, the mean excretion of dehydrosparteines in our 10 subjects was 20.6% ± 13.2%. The overall rank correlation between the sparteine and debrisoquin metabolic ratios was low (r s = 0.47), while the coefficient of determination for linear regression (r 2 ) was only 0.17. Our data show that the ability of Ghanaians to oxidize sparteine is largely independent of their capacity for debrisoquin oxidation and is indicative of a major interethnic difference in the genetic control of these reactions. Clinical Pharmacology and Therapeutics (1985) 37, 512–521; doi: 10.1038/clpt.1985.81

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here